Close Menu

NEW YORK (GenomeWeb) – Investment bank First Analysis has initiated coverage of NeoGenomics with an Overweight rating and a price target of $11, citing in part the company's more robust scale and product portfolio after its acquisition of Clarient.

With the integration of Clarient "well underway, NeoGenomics is positioned to take cancer diagnostics market share as a result of its increased scale and now broader and more comprehensive suite of offerings," First Analysis analyst Joseph Munda wrote in a research note Monday.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

A New Zealand minister says the country's genetic modification laws need to be re-examined to help combat climate change, the New Zealand Herald reports.

A new analysis finds some cancers receive more nonprofit dollars than others.

An Australian mother's conviction in the deaths of her children may be re-examined after finding that two of the children carried a cardiac arrhythmia-linked gene variant.

In Science this week: comparative analysis of sex differences in mammal gene expression, and more.